ENX-104

Engrail Therapeutics INC · Phase 1 active Small molecule

At a glance

Generic name	ENX-104
Sponsor	Engrail Therapeutics INC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ENX-104 CI brief — competitive landscape report
ENX-104 updates RSS · CI watch RSS
Engrail Therapeutics INC portfolio CI